Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the effects of valacyclovir on patients who have
hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which
causes genital herpes. Some persons with genital herpes have sores in their private areas but
most persons do not have any symptoms at all. Valacyclovir is a medication which is commonly
used to treat or prevent outbreaks of genital herpes. This medication is already approved by
the Food and Drug Administration to treat genital herpes. Valacyclovir has not been approved
to treat chronic hepatitis C.
The study will take 16 weeks. Participants will be assigned to take either the study drug,
valacyclovir, or a sugar pill that looks exactly like valacyclovir. The researchers and the
persons participating will not know which medication they are receiving. Study visits will
occur every two weeks and will take approximately 3-45 minutes. All study visits will occur
at the G.V. Sonny Montgomery VA Medical Center.